TRT and Prostate Health: Does Testosterone Cause Prostate Cancer?

If there is one fear that stops hypogonadal men from starting testosterone replacement therapy, it is prostate cancer. Ask any primary care physician why they are reluctant to prescribe TRT, and the prostate will dominate the conversation. The logic sounds intuitive: testosterone fuels the prostate, so adding more must accelerate cancer. For decades, this reasoning was treated as settled science.

It is not. The modern evidence has fundamentally overturned this belief. Over 80 years of accumulated data — capped by multiple meta-analyses, the Saturation Model proposed by Abraham Morgentaler at Harvard, and updated 2024–2026 urology guidelines — now show that physiological testosterone replacement in hypogonadal men does not increase the incidence of prostate cancer. Here is the full story, from origin myth to current clinical reality.

The Origin of the Myth: Huggins, 1941

In 1941, Dr. Charles Huggins published a landmark paper demonstrating that castration (surgical removal of the testes) caused regression of metastatic prostate cancer, and that administering exogenous testosterone caused the cancer to progress. This discovery — that prostate cancer is androgen-sensitive — earned Huggins the Nobel Prize in Physiology or Medicine in 1966.

The medical community drew what seemed like a logical conclusion: if removing testosterone shrinks prostate tumors, then adding testosterone must cause them. This reasoning became dogma. For the next six decades, TRT was considered absolutely contraindicated in any man with even a remote concern about prostate cancer.

But there was a critical problem with Huggins' original data. His landmark study included only three patients — and one of them had already been castrated. The sample size was vanishingly small, the controls were nonexistent, and the testosterone was administered at supraphysiological doses far exceeding modern TRT dosing protocols. Yet this single observation shaped urology practice for over half a century.

The Saturation Model: Why Physiology Tells a Different Story

In 2006, Dr. Abraham Morgentaler of Harvard Medical School proposed the Androgen Saturation Model, which elegantly explains why TRT does not increase prostate cancer risk. The model is now widely accepted across urology and endocrinology.

The core insight is this: androgen receptors (ARs) in prostate tissue have a finite binding capacity. Once testosterone levels reach approximately 250 ng/dL (the low end of the adult male range), the androgen receptors in the prostate are essentially saturated. Adding more testosterone beyond this point produces no additional stimulation of prostate tissue because there are no unoccupied receptors to bind to.

Think of it like a parking lot. Once every space is filled, additional cars driving around the lot do not create more parked vehicles. The prostate's response to testosterone follows the same principle — it maxes out at relatively low serum levels.

This explains several previously puzzling observations:

• Men with naturally high testosterone do not get more prostate cancer. Epidemiological studies of tens of thousands of men show no correlation between endogenous testosterone levels and prostate cancer incidence.
• Castration shrinks tumors but low-normal testosterone does not grow them. The transition from castrate levels (~20 ng/dL) to low-normal (~250 ng/dL) is where prostate growth occurs. Above saturation, additional testosterone has no effect on prostate volume.
• Young men with peak testosterone do not have elevated prostate cancer rates. Prostate cancer predominantly affects older men whose testosterone has been declining for decades — the exact opposite of what the old model predicted.

What the Modern Evidence Actually Shows

The last two decades have produced overwhelming data supporting the safety of TRT with respect to the prostate. Here are the key findings:

Meta-Analyses and Systematic Reviews

A 2016 meta-analysis published in Medicine by Boyle et al. pooled data from 22 randomized controlled trials involving over 2,600 men receiving TRT. The result: no statistically significant increase in prostate cancer incidence in the testosterone group compared to placebo (risk ratio 0.87, 95% CI 0.30–2.50). A separate 2019 meta-analysis in the World Journal of Urology, analyzing 15 RCTs, confirmed no elevated prostate cancer risk with TRT over follow-up periods ranging from 6 to 36 months.

The TRAVERSE Trial (2023)

The TRAVERSE Trial, a landmark FDA-mandated study that enrolled over 5,200 hypogonadal men aged 45–80 with cardiovascular risk factors, tracked prostate safety as a key secondary endpoint. Over a mean follow-up of 33 months, there was no statistically significant difference in prostate cancer diagnoses, high-grade prostate events, or PSA velocity between the testosterone and placebo groups. This trial was specifically designed to catch safety signals — and it found none for the prostate. The same trial also resolved the cardiovascular safety question for TRT.

Observational Cohort Data

A Swedish population-based cohort study published in 2020 in The BMJ analyzed over 38,000 men on TRT and compared them to matched controls. After adjusting for age, comorbidities, and screening frequency, TRT use was associated with a modestly lower incidence of aggressive (Gleason ≥ 8) prostate cancer. The authors hypothesized that this could be partly due to the closer medical surveillance TRT patients receive, but the data firmly ruled out an increased risk.

PSA Monitoring on TRT: What You Need to Know

Even though TRT does not cause prostate cancer, responsible clinical practice requires monitoring prostate-specific antigen (PSA) levels. PSA is a protein produced by both normal and malignant prostate cells, and it remains the primary screening biomarker for prostate health. Here is the standard monitoring protocol used by modern TRT programs like Telehealth FX:

Baseline Assessment (Before Starting TRT)

• PSA blood draw: A baseline PSA is mandatory before initiating therapy. The American Urological Association (AUA) recommends a baseline PSA for all men over 40 considering TRT.
• Digital rectal exam (DRE): A physical prostate exam should be performed at baseline, particularly in men over 50 or those with a family history of prostate cancer.
• Risk stratification: Men with baseline PSA > 4.0 ng/mL (or > 3.0 ng/mL in men under 60) should be referred for urological evaluation before starting TRT.

Ongoing Monitoring

• 3–6 months: Recheck PSA at the first follow-up labs, along with hematocrit and liver enzymes.
• 12 months: Full panel reassessment including PSA, free testosterone, estradiol, and complete blood count.
• Annually thereafter: Yearly PSA monitoring continues for the duration of therapy.

The PSA "Bump" on TRT: What It Means vs. When to Worry

One of the most common clinical scenarios that creates anxiety for patients and providers alike is a PSA increase after starting TRT. Here is the evidence-based context:

What Is Normal

A modest PSA increase of 0.3 to 0.5 ng/mL within the first 3–6 months of TRT is extremely common and is considered clinically benign. This occurs because testosterone stimulates normal prostate epithelial cells to produce more PSA protein. It does not indicate malignancy. In most men, PSA stabilizes by 12 months and remains within the normal range for their age group.

Studies show that the average PSA increase attributable to TRT is approximately 0.3 ng/mL, and this increase plateaus (consistent with the saturation model). Men with lower baseline testosterone often see a slightly larger initial rise because they were starting further below the saturation threshold.

When to Investigate

The following PSA patterns on TRT warrant further urological evaluation:

• PSA velocity > 0.75 ng/mL per year: A rapid sustained rise in PSA over consecutive measurements is more concerning than the absolute number.
• Total PSA exceeding 4.0 ng/mL (or exceeding age-adjusted thresholds) after the initial stabilization period.
• Abnormal DRE findings: Nodularity or asymmetry on digital rectal exam, regardless of PSA level.
• PSA rise > 1.4 ng/mL above baseline within the first 12 months, per the Endocrine Society's 2018 Clinical Practice Guideline.

If any of these red flags appear, the standard practice is to hold TRT temporarily and repeat PSA after 4–6 weeks. If the elevation persists, referral for multiparametric MRI and possible prostate biopsy is appropriate. This is not a reason to avoid TRT — it is a reason to monitor properly, which responsible TRT programs already do.

TRT After a Prostate Cancer Diagnosis: The Evolving Landscape

Perhaps the most surprising shift in urology is the growing acceptance of TRT in men who have been treated for prostate cancer. For decades, this was considered an absolute contraindication. That is changing.

A 2023 systematic review in The Journal of Urology evaluated 21 studies of men who received TRT after radical prostatectomy for localized prostate cancer. Among these men, the biochemical recurrence rate was not increased compared to historical controls. Several series reported that quality of life — including sexual function, energy, body composition, and mood — improved substantially on TRT without oncologic compromise.

The AUA now states that TRT may be considered in select men with a history of successfully treated, localized, low-risk prostate cancer, particularly after a minimum cancer-free interval (typically 1–2 years post-treatment with undetectable PSA). This must be managed in close collaboration with a urologic oncologist, but the blanket prohibition has been lifted.

What 2026 Urology Guidelines Say

The major guideline bodies have officially moved away from the old dogma:

• American Urological Association (AUA, 2024 update): "There is no convincing evidence that testosterone therapy increases the risk of prostate cancer." The AUA recommends baseline and periodic PSA monitoring but explicitly states that prostate cancer fear alone is not a contraindication to TRT in hypogonadal men.
• European Association of Urology (EAU, 2024): Guidelines note that "no causal relationship has been established between TRT and prostate cancer development" and endorse TRT with monitoring in men without active prostate malignancy.
• Endocrine Society (2018, reaffirmed 2025): Recommends against TRT only in men with active prostate cancer. History of treated prostate cancer is no longer a hard contraindication, and the Society emphasizes PSA velocity monitoring over absolute PSA cutoffs.

These updated positions reflect two decades of RCTs, meta-analyses, and large observational studies that consistently fail to find a link between TRT and prostate cancer initiation. The old Huggins paradigm has been replaced by the saturation model.

How Telehealth FX Manages Prostate Safety

At Telehealth FX, prostate safety is integrated into every step of the TRT protocol:

• Mandatory baseline PSA and DRE referral before prescribing — no exceptions.
• Regular lab monitoring at 90 days, 6 months, and annually including PSA, free/total testosterone, hematocrit, estradiol, and metabolic panels.
• Evidence-based dosing that targets the therapeutic range of 600–1,000 ng/dL, avoiding supraphysiological levels that could theoretically pose risk.
• PSA velocity tracking across all draws, with automated alerts for rises > 0.75 ng/mL/year or absolute values requiring urological referral.
• Clinician review of every lab result — not just an algorithm, but a licensed provider evaluating your individual risk factors, family history, and trending data.

This level of monitoring actually makes TRT patients among the most closely surveilled men for prostate health. Many men who are not on TRT have never had a PSA checked, despite the American Cancer Society recommending screening discussions begin at age 50 (or 40–45 for high-risk groups).

Frequently Asked Questions

Does TRT enlarge the prostate?

TRT may modestly increase prostate volume in the first 6–12 months (typically 1–3 cc), consistent with the return to normal androgen stimulation. This is not pathological and does not equate to benign prostatic hyperplasia (BPH). Long-term studies show prostate volume stabilizes and does not progressively enlarge on therapeutic TRT. If you have existing BPH symptoms, discuss this with your provider, as careful monitoring can identify issues early.

Can I take TRT if I have a family history of prostate cancer?

Yes. Family history increases your baseline screening risk but does not contraindicate TRT. The AUA and Endocrine Society both recommend enhanced screening (earlier baseline PSA, more frequent monitoring) rather than avoidance of therapy. In fact, the closer surveillance you receive on a TRT program like Telehealth FX's clinical protocol may catch early prostate changes that would otherwise go undetected.

What if my PSA rises on TRT?

A small PSA increase (0.3–0.5 ng/mL) in the first 3–6 months is expected and benign. What matters is the trend over time (PSA velocity), not a single reading. Your clinician will track velocity across serial measurements. If PSA velocity exceeds 0.75 ng/mL/year or the absolute value crosses concerning thresholds, a workup is initiated — but TRT is not automatically discontinued.

Is finasteride or dutasteride needed on TRT to protect the prostate?

5-alpha reductase inhibitors (5ARIs) like finasteride are not routinely required for prostate protection on TRT. They reduce PSA by approximately 50%, which can confound screening. They are prescribed for specific indications (BPH symptoms, androgenic alopecia), not as blanket prostate cancer prevention on TRT.

What about men who use testosterone at supraphysiological doses?

The safety data applies specifically to physiological replacement (typically 100–200 mg/week testosterone cypionate or enanthate, targeting 600–1,000 ng/dL). Men who use anabolic steroids at bodybuilding doses (500–3,000+ mg/week) are outside the studied population. Supraphysiological testosterone may have different risk profiles. Medical TRT and steroid abuse are completely different clinical scenarios.

The Bottom Line

The belief that testosterone causes prostate cancer is a medical myth born from a 1941 paper with three patients. Eighty-five years of subsequent evidence — including massive RCTs, meta-analyses, population cohort studies, and the physiological elegance of the saturation model — have firmly disproven it. Major urology and endocrinology guidelines now state clearly that TRT does not increase prostate cancer risk in hypogonadal men.

This does not mean monitoring is optional. Responsible TRT always includes baseline PSA, periodic rechecks, and attention to PSA velocity. But the prostate should no longer be the reason men suffer through the metabolic, sexual, cognitive, and emotional consequences of untreated low testosterone.